FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q89581478> ?p ?o ?g. }

• Q89581478 description "artículu científicu espublizáu en febreru de 2020" @default.
• Q89581478 description "im Februar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
• Q89581478 description "scientific article published on 05 February 2020" @default.
• Q89581478 description "wetenschappelijk artikel" @default.
• Q89581478 description "наукова стаття, опублікована 5 лютого 2020" @default.
• Q89581478 name "NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progre" @default.
• Q89581478 name "NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progre" @default.
• Q89581478 type Item @default.
• Q89581478 label "NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progre" @default.
• Q89581478 label "NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progre" @default.
• Q89581478 prefLabel "NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progre" @default.
• Q89581478 prefLabel "NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progre" @default.
• Q89581478 P1433 Q89581478-E56DA8FF-BFFA-4609-A3E4-F32BD3EECD3C @default.
• Q89581478 P1476 Q89581478-2F95E067-0665-4ED7-975E-4D6A45BFD09B @default.
• Q89581478 P2093 Q89581478-126A1A50-FD7E-4CD5-8E68-6A7DF31232D5 @default.
• Q89581478 P2093 Q89581478-2B86703C-355D-4719-803A-584B67CA37F4 @default.
• Q89581478 P2093 Q89581478-31211FDB-0942-47F6-BC80-3B378D02FB78 @default.
• Q89581478 P2093 Q89581478-42FC9151-2AAE-4D54-A97F-3911D7A95DE0 @default.
• Q89581478 P2093 Q89581478-4B96D077-14C7-429A-B880-6F9422878EC1 @default.
• Q89581478 P2093 Q89581478-4F558891-D5A5-4734-B37A-186FC4965B76 @default.
• Q89581478 P2093 Q89581478-5514BD69-4C99-4EA4-B08D-C11C65A4C99C @default.
• Q89581478 P2093 Q89581478-5644A982-FCC6-4A2E-8C05-CBD06CEB23C4 @default.
• Q89581478 P2093 Q89581478-616DBA01-D371-4EA3-91FB-3ECC4A74F341 @default.
• Q89581478 P2093 Q89581478-63CB30FD-B8CC-4DF4-8942-98D4DCB0ADF3 @default.
• Q89581478 P2093 Q89581478-70495023-CF66-41ED-AB22-5C03AAAD1104 @default.
• Q89581478 P2093 Q89581478-844DB179-66F1-46E3-87D5-DC6022C247EF @default.
• Q89581478 P2093 Q89581478-88429238-9557-4317-A0FA-A2A8BFB7080B @default.
• Q89581478 P2093 Q89581478-88C2CBFD-480B-46C3-A988-36825E8EDC70 @default.
• Q89581478 P2093 Q89581478-98ACFC6C-9A83-43BB-B7CB-D6DAE7D5EBDF @default.
• Q89581478 P2093 Q89581478-B34F01EC-CAA9-4885-9DF1-A68257FC8625 @default.
• Q89581478 P275 Q89581478-f475cbd4-a8d4-479f-b79d-7f6ba6e4e175 @default.
• Q89581478 P2860 Q89581478-215FACE5-BE85-4E46-AE9E-5B9EC4EB5DA8 @default.
• Q89581478 P2860 Q89581478-2B94A320-FE0E-47E4-848F-D5609EDE6D43 @default.
• Q89581478 P2860 Q89581478-2BCE0963-3BED-4971-87FC-B6208AF15045 @default.
• Q89581478 P2860 Q89581478-45D7F63C-9644-4B29-B31B-940DE1DF1359 @default.
• Q89581478 P2860 Q89581478-55AAF54B-6D88-4FEE-A3E1-FE9F74710AFE @default.
• Q89581478 P2860 Q89581478-562331BB-E6D4-419A-9887-17DE20C5F527 @default.
• Q89581478 P2860 Q89581478-5CDF1734-2F91-4FF5-97EF-61C05F46B296 @default.
• Q89581478 P2860 Q89581478-5E0A9552-8EB5-427C-8590-69E8FECBC0F0 @default.
• Q89581478 P2860 Q89581478-60BD15B3-101B-47C5-B487-9F9320AAAC56 @default.
• Q89581478 P2860 Q89581478-6FE6E363-4267-483D-AF60-470B41F35312 @default.
• Q89581478 P2860 Q89581478-7478B862-5F11-4B7D-A810-D9AC566CA234 @default.
• Q89581478 P2860 Q89581478-747CF68D-6232-4023-B631-021B6CB756C6 @default.
• Q89581478 P2860 Q89581478-85418D4C-34F4-4947-A488-3E1A97E27242 @default.
• Q89581478 P2860 Q89581478-B76D358A-43DA-49AF-A625-9A361BACB7A1 @default.
• Q89581478 P2860 Q89581478-BBE35169-9033-48C2-8139-56B56E507C69 @default.
• Q89581478 P2860 Q89581478-DB930B26-A735-4F66-AC6B-2EA7D213CE8A @default.
• Q89581478 P2860 Q89581478-DFB6B865-BD39-4327-B192-F82699F54034 @default.
• Q89581478 P2860 Q89581478-E2EA7E98-76B6-44BB-A063-FAEAD06D6208 @default.
• Q89581478 P2860 Q89581478-E5805B77-A117-4A50-B3B7-D3BDDC3988E8 @default.
• Q89581478 P2860 Q89581478-EA5F4DF2-C238-4CDA-9C12-19FC9EC94E77 @default.
• Q89581478 P2860 Q89581478-F62912B8-E75F-4039-9BDD-6CF0B8C5823D @default.
• Q89581478 P304 Q89581478-3D82B8A3-1141-4597-9EB5-AE017480AA6F @default.
• Q89581478 P31 Q89581478-C6882C2C-CD38-45BC-9E96-6C48C2E38098 @default.
• Q89581478 P356 Q89581478-042D3058-F970-42DD-B310-A349F134ACD4 @default.
• Q89581478 P433 Q89581478-EC574DA6-8E18-4FB8-A2A8-482890114FF9 @default.
• Q89581478 P478 Q89581478-2CA0B82B-53D9-4402-BF0D-2E143C7A02DF @default.
• Q89581478 P50 Q89581478-2EC1B54F-E003-49AE-A636-3F19D459F2E4 @default.
• Q89581478 P50 Q89581478-3CD63001-9275-422A-A279-D5C2DD22FF0E @default.
• Q89581478 P50 Q89581478-BC697E22-4C22-436B-BC74-5E4EA9BE5492 @default.
• Q89581478 P577 Q89581478-2036D17A-CA54-466A-9659-812B8EDEA5CC @default.
• Q89581478 P6216 Q89581478-6c46e182-8dfd-4467-b34c-a17812628ef7 @default.
• Q89581478 P698 Q89581478-C1495858-314D-4CA3-8CB4-96551D35E946 @default.
• Q89581478 P921 Q89581478-09086C56-5A8F-477A-971D-34466A6E4AE8 @default.
• Q89581478 P921 Q89581478-0ADD2C68-C046-4C43-AEBC-80C5C044C71E @default.
• Q89581478 P921 Q89581478-24FAABDC-8546-4D69-81C3-7C0CCDFE4270 @default.
• Q89581478 P921 Q89581478-BB16B7D0-4B0A-412B-AC0D-9D637A7DFF77 @default.
• Q89581478 P921 Q89581478-D7054D8E-344B-4B12-86BC-F946E480B8E8 @default.
• Q89581478 P932 Q89581478-A3716B4D-BC59-4A94-85D6-AB2611E93404 @default.
• Q89581478 P356 BMJOPEN-2019-034527 @default.
• Q89581478 P698 32029495 @default.
• Q89581478 P1433 Q17003470 @default.
• Q89581478 P1476 "NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)" @default.
• Q89581478 P2093 "Angela Lamarca" @default.
• Q89581478 P2093 "David A Cairns" @default.
• Q89581478 P2093 "Emma Batman" @default.
• Q89581478 P2093 "Helen Howard" @default.
• Q89581478 P2093 "Ian Chau" @default.
• Q89581478 P2093 "Jayne Swain" @default.
• Q89581478 P2093 "Jonathan Wadsley" @default.
• Q89581478 P2093 "Juan W Valle" @default.
• Q89581478 P2093 "Judith Cave" @default.
• Q89581478 P2093 "Lucy Wall" @default.
• Q89581478 P2093 "Nicholas Reed" @default.
• Q89581478 P2093 "Olusola Faluyi" @default.
• Q89581478 P2093 "R Hubner" @default.
• Q89581478 P2093 "Rohini Sharma" @default.
• Q89581478 P2093 "Tim Meyer" @default.
• Q89581478 P2093 "Wasat Mansoor" @default.
• Q89581478 P275 Q20007257 @default.
• Q89581478 P2860 Q28131668 @default.
• Q89581478 P2860 Q33373397 @default.
• Q89581478 P2860 Q33384569 @default.
• Q89581478 P2860 Q33417320 @default.
• Q89581478 P2860 Q33866374 @default.
• Q89581478 P2860 Q34729191 @default.
• Q89581478 P2860 Q35713556 @default.
• Q89581478 P2860 Q36200313 @default.
• Q89581478 P2860 Q36594133 @default.
• Q89581478 P2860 Q36725667 @default.

• next